Clinical Trials Browser

Hematologic Diseases × idecabtagene vicleucel × 90 days × Clear all

NCT05032820 2026-05-19

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Phase 2 Completed

40 enrolled 32 charts

Hematologic Diseases, Multiple Myeloma